Only weeks after purchasing a royalty buyout option for its lead asset duvelisib (IPI-145) from Takeda’s Millennium Pharmaceuticals, Infinity Pharmaceuticals has licensed the phosphoinositide-3-kinase (PI3K)-delta/gamma inhibitor to AbbVie in a deal potentially worth US$805 M. AbbVie has also agreed to invest up to US$750 M to fund an R&D collaboration focused on age-related diseases with Google-backed start-up Calico Life Sciences.